Participant Characteristics by Baseline Survey Response Status (n = 3,071)
| Non-Respondents | Respondents | p | |
|---|---|---|---|
| N | 1,352 | 1,719 | |
| Age, M (SD) | 58.3 (14.5) | 61.7 (14.0) | <0.001 |
| Age <60, n (%) | 711 (52.6) | 708 (41.2) | <0.001 |
| Female, n (%) | 705 (52.1) | 934 (54.3) | 0.23 |
| BMI (kg/m2), M (SD) | 32.5 (8.1) | 32.5 (7.8) | 0.93 |
| Race | |||
| White, n (%) | 876 (64.8) | 1,256 (73.1) | <0.001 |
| Black, n (%) | 265 (19.6) | 329 (19.1) | 0.75 |
| Asian, n (%) | 143 (10.6) | 70 (4.1) | <0.001 |
| All else, n (%) | 68 (5.0) | 64 (3.7) | 0.08 |
| Diabetes, n (%) | 340 (25.1) | 433 (25.2) | 0.98 |
| Cardiovascular disease, n (%) | 192 (14.2) | 320 (18.6) | 0.001 |
| SBP (mm Hg), M (SD) | 158.1 (16.0) | 158.0 (14.8) | 0.82 |
| DBP (mm Hg), M (SD) | 93.0 (13.8) | 90.6 (13.9) | <0.001 |
| Number of BP medications | |||
| 0, n (%) | 235 (17.4) | 231 (13.4) | 0.002 |
| 1, n (%) | 427 (31.6) | 524 (30.5) | 0.51 |
| 2, n (%) | 380 (28.1) | 520 (30.3) | 0.19 |
| 3+, n (%) | 310 (22.9) | 444 (25.8) | 0.06 |
| Drug classes used | |||
| ACE-inhibitor, n (%) | 402 (29.7) | 527 (30.7) | 0.58 |
| ARB, n (%) | 294 (21.7) | 414 (24.1) | 0.13 |
| Diuretic, thiazide, n (%) | 413 (30.5) | 546 (31.8) | 0.47 |
| Diuretic, loop, n (%) | 82 (6.1) | 125 (7.3) | 0.19 |
| Beta blocker, n (%) | 466 (34.5) | 675 (39.3) | 0.006 |
| CCB DHP, n (%) | 342 (25.3) | 453 (26.4) | 0.51 |
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker, BMI, body mass index; CCB, calcium channel blocker; DHP, dihydropyridine.